Acetyl-Histone H3 (Lys36) Antibody

What experimental controls are essential when using Acetyl-Histone H3 (Lys36) Antibody in western blotting?

Methodological Answer:
To ensure specificity and reliability, implement the following controls:

For advanced studies, use CRISPR-edited cell lines lacking H3K36 acetylation as a stringent negative control to confirm antibody specificity .

Methodological Answer:
Select antibody type based on experimental goals:

For ChIP-seq or flow cytometry, monoclonal antibodies (e.g., Alexa Fluor® 647-conjugated ) are preferred due to lot consistency and reduced background. Polyclonal antibodies are better suited for western blot when broad signal detection is required .

How to optimize antibody dilution for different applications?

Methodological Answer:
Dilution varies by technique and antibody type:

Troubleshooting Tips:

• Weak signal: Increase primary antibody concentration or extend incubation time.

• High background: Use blocking agents (e.g., 5% BSA) or pre-clear lysates with non-specific IgG .

How to address cross-reactivity concerns with Acetyl-Histone H3 (Lys36) Antibody?

Methodological Answer:
Minimize false positives with these strategies:

• Peptide Competition: Pre-incubate antibody with acetylated H3K36 peptide to block epitope recognition .

• Knockout Controls: Use H3K36ac-deficient cells (e.g., via CRISPR) to confirm absence of signal .

• Species Validation: Confirm reactivity with target species (e.g., human, mouse, rat) .

Case Study: A study comparing H3K36ac in human and rat samples found equivalent reactivity, but monkey cross-reactivity was untested . Always validate species-specificity empirically.

What are the implications of H3K36ac and H3K36me3 coexisting in the same genomic region?

Methodological Answer:
This co-occurrence suggests complex transcriptional regulation:

Contradiction Resolution: Use sequential ChIP (ReChIP) to determine if both marks co-occur on the same nucleosome. This approach revealed that H3K36ac and H3K36me3 are mutually exclusive in yeast .

How to troubleshoot inconsistent results when using Acetyl-Histone H3 (Lys36) Antibody across different cell lines?

Methodological Answer:
Inconsistencies often arise from biological or technical factors:

Advanced Protocol: Perform quantitative acetylomics (e.g., LC-MS/MS) to correlate antibody signal with absolute acetylation levels.

What are the best practices for interpreting H3K36ac levels in relation to gene expression?

Methodological Answer:
Integrate complementary data to validate findings:

• Correlation with RNA Pol II: Co-stain with anti-RNA Pol II antibodies to confirm active transcription .

• ChIP-seq Profiling: Map H3K36ac peaks to gene promoters and correlate with RNA-seq data.

• Epigenetic Context: Analyze co-occurring marks (e.g., H3K4me3) to distinguish active enhancers from promoters .

How to validate antibody specificity using peptide competition?

Methodological Answer:
Protocol:

• Pre-incubate antibody with acetylated H3K36 peptide (10× molar excess).

• Compare peptide-treated lanes to untreated controls in western blot.

• Expected Outcome: Signal reduction >50% confirms specificity .

Limitations: Peptide competition may not detect cross-reactivity with non-histone proteins. Supplement with WBIP (Western Blot in Parallel) controls .

What are the advantages of using recombinant monoclonal antibodies over traditional polyclonal ones?

Methodological Answer:
Recombinant monoclonal antibodies (e.g., D9T5Q ) offer:

• Lot-to-Lot Consistency: Eliminates variability in animal-derived antisera.

• Animal-Free Production: Aligns with ethical and regulatory standards.

• Conjugation Flexibility: Pre-labeled versions (e.g., Alexa Fluor® 647) streamline workflows .

Trade-offs: Higher cost and limited epitope recognition compared to polyclonal antibodies.